Anti-tumour activity of TAK-788 in NSCLC patients with EGFR exon 20 insertions

Bookmark and Share
Published: 18 Jun 2019
Views: 595
Dr Joel Neal - Stanford University, Stanford, USA

Dr Joel Neal talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about a study looking at the anti-tumour activity of oral investigational EGFR/HER2 inhibitor TAK-788 in NSCLC patients with EGFR exon 20 insertions.

He explains that EGFR mutant NSCLC with exon 20 insertions is a very particular type of the cancer.

It makes up only 5% of EGFR mutant lung cancer with EGFR mutant lung cancer making up just 15% of NSCLC.

Dr Neal explains that the data presented is mainly from one of the extension cohorts and that out of these patients a 43% response rate was seen, comparing favourably to other drugs in its class.